Non-Hodgkin Lymphoma – VJRegenMed

Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL

Anya Kerkache — Thu, 09 Mar 2023 11:31:47 +0000

Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of two studies evaluating the LV20.19 CAR-T product in patients with Richter’s transformation and in patients with heavily pretreated mantle cell lymphoma (MCL; NCT04186520). Out of the six patients with Richter’s transformation who were evaluated, four achieved a durable remission and the overall response rate (ORR) was 100%. Patients presented a unique toxicity profile, with a high incidence of hemophagocytic lymphohistiocytosis (HLH)-like toxicity. In MCL, eight of the 14 patients in the study met the primary endpoint, and the ORR at day 90 was 100%. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy

Anya Kerkache — Thu, 26 Jan 2023 12:12:01 +0000

Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy outcomes in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Europe and the US. Investigators observed significantly lower progression-free survival (PFS) in the European group, as well as significantly reduced radiographic response. Potential reasons for these differences included an adverse risk profile in European patients, logistical challenges resulting in longer vein-to-vein times, and the more frequent use of  tisagenlecleucel (tisa-cel) over axicabtagene ciloleucel (axi-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL

Anya Kerkache — Thu, 26 Jan 2023 12:11:30 +0000

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Australia, reports results from the CARBON Phase I dose-escalation study (NCT04035434), testing the safety and efficacy of a novel allogeneic CRISPR-Cas9-engineered CAR-T product, CTX110, in heavily pre-treated patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The study reported that the CAR-Ts showed clinical activity with the ability to expand in the body, and a low risk of graft-versus-host disease (GvHD). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL

Anya Kerkache — Thu, 26 Jan 2023 12:11:27 +0000

Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, describes the mechanism of action of huCART19-IL18, a 4th generation autologous CAR T-cell product, and outlines findings from a first-in-human trial investigating the efficacy of huCART19-IL18 in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) (NCT04684563). Results from this study so far have been encouraging, with no unexpected toxicities being recorded and some patients already achieving complete response. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma

Anya Kerkache — Thu, 26 Jan 2023 12:11:24 +0000

Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, briefly describes an ongoing multi-center clinical trial investigating the efficacy and safety of CD20 CAR-T cell therapy in patients with Waldenström’s macroglobulinemia (WM) and CNS lymphoma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

LMY-920 in non-Hodgkin lymphoma

Simon Ng — Mon, 14 Feb 2022 17:40:19 +0000

Patients with B-cell non-Hodgkin lymphoma (NHL) can progress on current anti-CD19 chimeric antigen receptor (CAR) T-cell therapies due to antigen escape. Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, provides an overview of LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, which consists of three different antigens on the CAR T-cell. The three markers prevents antigen escape and the therapy additionally contains no foreign linkers, reducing immunogenicity. An Investigational New Drug Application (IND) will be imminently filed for LMY-920, with the therapy aiming to target NHL and mantle cell lymphoma (MCL). This interview took place at Advanced Therapies Week 2022.

Challenges of CAR T-cell therapy for AML: is CD38 the answer?

admin_vjr_user — Thu, 05 Aug 2021 11:33:45 +0000

Lei Yu, MD, PhD, Shanghai Unicar-Therapy Biomed-Pharmaceutical Technology Co. Ltd, China, explains that chimeric antigen receptor (CAR) T-cell therapies have been effective in treating hematologic B-cell malignancies, as they contain several antigens exclusive to the B-cell lineage, such as CD19, that can be targeted without causing significant harm to the patient. A key challenge facing CAR T-cell therapy for AML, however, is the identification of AML-specific target antigens, since myeloid antigens are often co-expressed on healthy bone marrow cells, which when targeted with CAR T-cells can cause fatal myeloablation. CD38 is being investigated as a target antigen for AML CAR T-cell therapy, as it is expressed on AML cells but not healthy bone marrow cells. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

CAR-T in DLBCL: 4-year follow-up data from ZUMA-1

Marta Palhas — Fri, 26 Feb 2021 14:08:28 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the four-year follow-up data from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) in adult patients with refractory diffuse large B-cell lymphoma (DLBCL). The four-year overall survival rate among patients after a single infusion of axi-cel was 44%. These are very encouraging results considering the heavily pre-treated patient population included in the pivotal clinical trial. Furthermore, there were no additional toxicity signs reported in this long-term follow-up analysis. This interview took place during the 3rd European CAR T-cell Meeting.

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

Marta Palhas — Fri, 26 Feb 2021 14:08:26 +0000

CD19 CAR T-cells are transforming the treatment of relapsed or refractory (R/R) B-cell malignancies. However, complete responses are not seen in all patients, and in a significant proportion, these responses are not durable. Jordan Gauthier, MD, MSc, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses second infusions of CD19 CAR T-cells (CART2) as a possible approach to improve outcomes in patients with R/R B-cell malignancies. An analysis of the outcomes after CART2 in patients with R/R acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia treated on a Phase I/II clinical trial of CD19 CAR T-cells of defined composition showed that CART2 was feasible and safe in most patients. Additionally, two modifiable pre-treatment factors independently associated with better outcomes after CART2 were identified. This interview took place during the 3rd European CAR T-cell Meeting.

The future of CAR T-cell therapy in lymphoma

admin_vjr_user — Fri, 26 Feb 2021 14:08:21 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the future directions of CAR T-cell therapy in lymphoma. The availability of CAR-T has modified the treatment algorithm for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Indications for CAR T-cell therapy will likely expand to earlier lines of treatment and other lymphomas. Dr Sureda is looking forward to the data from three Phase III clinical trials comparing CAR T-cell therapies with autologous stem cell transplantation in patients with primary refractory disease. Additionally, strategies to improve efficacy and toxicity are certainly desirable. This interview took place during the 3rd European CAR T-cell Meeting.